Trial Profile
Phase II Study of Dasatinib in Advanced Non-Small Cell Lung Cancer With Ex Vivo and In Vivo Assessment of Tumor Target Modulation.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 06 Sep 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 27 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.